Detail akcie ProQR Therapeutics online

Business Summary: ProQR Therapeutics N.V. is a biotechnology company based in the Netherlands. The Company is engaged in the discovery and development of ribonucleic Acid (RNA)-based therapeutics for the treatment of severe genetic disorders. Main purpose of the Company is advancement of its Axiomer RNA-editing platform technology. That technology uses a cell’s own editing machinery called ADAR to make specific single nucleotide edits in RNA to reverse a mutation or modulate protein expression and could potentially yield a new class of medicines for both rare and prevalent diseases with unaddressed needs. The Company operates research pipeline that contains of RNA Therapy and AX-0810 Cholestatic Diseases (NTCP).
Financial Summary: BRIEF: For the six months ended 30 June 2025, ProQR Therapeutics NV revenues decreased 22% to EUR8.7M. Net loss increased from EUR10.4M to EUR22.3M. Revenues reflect Revenue decrease of 22% to EUR8.3M. Higher net loss reflects RNA based Therapeutics segment loss increase of 98% to EUR23.1M. Basic Earnings per Share excluding Extraordinary Items decreased from -EUR0.13 to -EUR0.21.